Studies have shown that the abnormal activation of the PI3K/Akt/mTOR/NF-κB signaling pathway induced by EGFR promotes the proliferation of glioma cells and is related to MGMT promoter methylation or expression, subsequently enhancing glioma drug resistance, and the efficacy of chemotherapy drugs such as TMZ is weakened due to drug resistance. The gene discussed is AKT1; the disease is central nervous system cancer.